L40.0 L29
Conditions
Interventions
Group 1: Patients with psoriasis and itch
It is a one-time investigation using the following techniques:
A) Quantitative sensory testing (QST). Thermal testing is carried out by means of a thermode
Sponsors
Klinik für Dermatologie, UKSH Campus Kiel
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Patients with psoriasis for at least 3 months with and without pruritus. Controlgroup (no skin diseases, no itch). - Patients with pruritus should suffer from pruritus for at least 6 weeks - patients with a stable anti-psoriatic treatment for at least 4 weeks (with the exemption of UV-therapy and systemic corticosteroids) and/or therapy-naiv patients. - no topical therapy for at least 3 weeks prior to testing in the location that will be evaluated - One psoriatic lesion should be located on the back and/or thighs and/or buttocks.
Exclusion criteria
Exclusion criteria: - pregnancy or breastfeeding - systemic corticosteroids or uv-therapy within four weeks prior to testing - intake of NSAR, analgetics, opioids or other medikations with an influence on itch within 7 days prior to testing. - intake of antidepressents or medication against migraine within four weeks prior to testing - intake of gabapentin within four weeks prior to testing - application of emolients on the day of testing - known intolerance of capsaicin, histamin, cowhadge or other relevant substances - other skin lesions than psoriasis (e.g. infection, tattoos) in the testlocation - patients with a known history of atopy - patients with a known history of polyneurophaty or other neurological diseases - patients with a history of diabetes - patients with a history of backpain - diseases that in the discretion of the investigators do not allow testing (e.g. psychosomatic or psychological diseases). - skin type IV-VI (Fitzpatrik) - patients/controlgroup unable to consent - drug or alcohol abuse
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The testing will take place at a certain time point. It is a one-time testing. Quantitativ sensoric testing: validation of peripheral functionality of Ab, Ad and C-fibers, as well as variation of central sensibilisation. endogenous pain-inhibition (CPM): central pain-inhibition will be measured using established CPM paradigm Stimulation with Cowhage, histamine and Natriumchlorid. | — |
Secondary
| Measure | Time frame |
|---|---|
| disease specific severity measures (e.g.: PASI, BSA) | — |
Countries
Germany
Contacts
Public ContactSascha Gerdes
Klinik für Dermatologie, UKSH Campus Kiel
Outcome results
None listed